Omeprazole-Model

Whole-body PBPK model of omeprazole as a substrate of CYP2C19 and CYP3A4 and an inhibitor of CYP2C19.

This repository contains:

• a PK-Sim snapshot (*.json) file of the current PBPK model
• static content (e.g. text blocks, *.md files) as inputs for an evaluation plan
• an evaluation plan (evaluation-plan.json) to create an evaluation report using the snapshot and static text blocks to display the performance of the model

The latest release of the snapshot of the model, the evaluation plan and the static content can be found here.

The latest release of the PK-Sim project model file and the respective evaluation report can be found here.

The presented PBPK model of omeprazole has been developed to be used in a PBPK Drug-DrugInteractions (DDI) network with omeprazole as a substrate of CYP2C19 and CYP3A4 and an inhibitor of CYP2C19. The development of this model is described in the publication by Kanacher et al. [1]

Contacts

For your questions and comments about the models please create a new issue. A full publication about models presented is available at: https://www.mdpi.com/1999-4923/12/12/1191 .

Code of conduct

Everyone interacting in the Open Systems Pharmacology community (codebases, issue trackers, chat rooms, mailing lists etc...) is expected to follow the Open Systems Pharmacology code of conduct.

Contribution

We encourage contribution to the Open Systems Pharmacology community. Before getting started please read the contribution guidelines. If you are contributing code, please be familiar with the coding standard.

License

The model code is distributed under the GPLv2 License.

References

[1] Kanacher, T. et al. A Physiologically-Based Pharmacokinetic (PBPK) Model Network for the Prediction of CYP1A2 and CYP2C19 Drug–Drug–Gene Interactions with Fluvoxamine, Omeprazole, S-mephenytoin, Moclobemide, Tizanidine, Mexiletine, Ethinylestradiol, and Caffeine. Pharmaceutics 2020, 12(12), 1191